Overcoming PARP Inhibitor and Platinum Resistance with WEE1 Inhibitors in Ovarian Cancer
Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment of high-grade epithelial ovarian cancer (EOC), with demonstrated efficacy in the recurrent as well as newly diagnosed disease. However, women with EOC inevitably acquire resistance to both platinum chemotherapy and PARPi....
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.09.047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|